{"schema_version":"secwatch.filing_event.v1","accession":"0001558370-24-012413","form_type":"8-K","ticker":"BPTH","cik":"0001133818","company_name":"BIO-PATH HOLDINGS, INC.","filed_at":"2024-08-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:12.257776+00:00","generated_at":"2026-05-31T08:12:07.233346+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Bio-Path reports solid tumor patient response to BP1001-A; AML patients show extended remission","bullets":["First patient at 90 mg/m2 dose of BP1001-A had 15% tumor reduction and stable disease after 6 cycles.","Patient is elderly female with gynecologic cancer, heavily pretreated with chemotherapy and surgeries.","Two elderly AML patients in Phase 2 triple combo (prexigebersen/decitabine/venetoclax) remain in complete remission: one at 16 cycles/21 months, another at 12 cycles/14 months.","Phase 1b of BP1001-A expected to begin after three monotherapy dose cohorts; will test combo with paclitaxel and gemcitabine.","Management highlights platform potential for targeted protein inhibition with favorable safety profile."],"urls":{"canonical":"https://secwatch.observer/filing/0001558370-24-012413","json":"https://secwatch.observer/filing/0001558370-24-012413.json","markdown":"https://secwatch.observer/filing/0001558370-24-012413.md","text":"https://secwatch.observer/filing/0001558370-24-012413.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024012413/0001558370-24-012413-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1133818/000155837024012413/bpth-20240821x8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T08:12:07.233346+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}